Trauma, Psychedelics, and Why Therapy Is the Conversation No One Finishes

THERAPY TOPICS • July 19, 2026

Last reviewed: July 2026 by Annie Wright, LMFT. This article is educational and does not constitute medical advice, a treatment plan, or an endorsement of any specific substance, provider, or protocol.

In short: Psychedelic-assisted therapy uses substances like psilocybin, MDMA, or ketamine to create temporary neurological and emotional openness, but the therapeutic relationship and the integration work that follows are what turn that openness into lasting change. This piece is educational, not a treatment recommendation.

Back in the Kitchen at 6 AM

Malika’s kitchen is dark except for the light over the stove, and she’s standing there at 6 AM in the Patagonia fleece she’s had since business school, holding a mug of tea that’s gone cold without her noticing. Six hours ago she was on a couch in a converted farmhouse an hour outside the city, coming down from a ketamine session that had cracked something open in her she hadn’t touched in fifteen years. Now she’s home. The dishwasher she loaded before she left is still running. Her phone has fourteen Slack notifications she hasn’t opened.

She picks up the phone anyway, out of habit, and scrolls without reading. A colleague’s conference photo. A headline about interest rates. None of it lands. The image that keeps surfacing instead is her mother’s hands at the kitchen sink in 1994, and the specific quality of the silence in that house. She sets the phone down. The kitchen is very quiet. She’s standing in her own home and she doesn’t, for a moment, know quite where “home” is anymore.

This is not a rare moment. I’ve sat with more than one ambitious, accomplished woman in the days after a psychedelic session who describes almost exactly this feeling: something enormous happened, and then she was handed back to her regular Tuesday with no map for what to do next. The session can crack open defenses that took decades to build, and offer a glimpse of a self that isn’t constantly performing. But a glimpse is not integration. Without a skilled person to help metabolize what surfaced, the insight can drift back into the ordinary noise of an inbox and a Tuesday morning.

This article sits at the intersection of two things I care about deeply: the genuine promise of psychedelic-assisted therapy for trauma, and the non-negotiable role of the therapeutic relationship in making that promise real. It’s educational, not a treatment recommendation, and it isn’t advocating for or against any particular substance. If you want the broader context for how trauma drives chronic strain in driven women’s lives, the piece on the stress behind the stress lays the neurobiological groundwork this article builds on.

What Is Psychedelic Therapy Actually Doing in the Brain?

In my work with clients, I’ve watched curiosity about psychedelic-assisted therapy grow year over year. It isn’t a passing trend. It’s a real shift in how the field thinks about trauma treatment, and understanding why requires looking at what’s actually happening in the brain, not what’s being promised in a wellness retreat brochure.

Psychedelics such as psilocybin, MDMA, and ketamine appear to temporarily quiet what’s called the Default Mode Network. Think of the DMN as your brain’s autopilot, the network responsible for self-referential thought, for rumination, for the running narration of “you” that never quite stops. For a lot of driven women, that narration is loud and constant: replaying the email you shouldn’t have sent, rehearsing tomorrow’s board meeting, cataloguing every way you fell short this week. When the DMN quiets, that narration goes quiet with it. Clients describe it as the first silence they’ve felt in years.

I recently spent time with Robin Carhart-Harris’s published work on this exact mechanism. Carhart-Harris, PhD, a neuroscientist who has spent much of his career studying the effects of psychedelics on brain activity, and whose research helped establish the DMN-suppression model that shapes most current clinical protocols, argues that disrupting these rigid self-referential patterns creates a genuine window for new ways of relating to old material. Not erasing memory. Altering the emotional charge sitting on top of it. That distinction matters more than almost anything else in this conversation, and I’ll come back to it.

During that window, the brain is unusually open to new input. It’s less like hitting a reset button, which implies starting from nothing, and more like a garden that’s just been turned over: receptive, but not blank, and entirely dependent on what gets planted in it next. The temporary loosening of ego boundaries can produce a felt sense of connection to other people, which is often deeply moving for someone who has spent years feeling isolated inside her own competence.

Why Doesn’t the Medicine Alone Hold?

Here’s the honest answer, and it’s not the one the wellness industry wants to sell you. The molecule is one part of a much larger process, and treating it as a complete solution is where things go wrong. Without the right container and a trained therapist’s guidance, the states that psychedelics catalyze can be disorienting. In some cases, without adequate screening and support, they can retraumatize rather than heal.

Picture the psychedelic experience as a door swinging open. It doesn’t walk you through. It creates a temporary state of psychological flexibility, and that’s precisely where integration becomes the entire point. Integration isn’t talking about your trip over coffee with a friend. It’s the ongoing, deliberate work of making sense of what surfaced and weaving it into how you actually live, how you argue with your spouse, how you show up in a Monday leadership meeting, how you let yourself rest on a Sunday afternoon.

I’ve been thinking about Rick Doblin’s decades of advocacy on this exact point. Doblin, PhD, founder and president of the Multidisciplinary Association for Psychedelic Studies, has spent nearly forty years arguing that psychotherapy is not an accessory to psychedelic treatment but the mechanism through which it works. Research from his organization shows that outcomes for conditions like PTSD improve substantially when the medicine is administered inside a structured therapeutic frame rather than alone. The relationship with the therapist provides the safety needed to make sense of an altered state after the fact.

Skip that step, and clients are often left holding more than they can metabolize: overwhelmed, disoriented, sometimes more disconnected than before the session. The brain may be more plastic in that window, but plasticity without direction doesn’t guarantee healing. It just guarantees change, and change without a guide can go anywhere. In my practice, the real, durable shift happens not in the session itself, but in the weeks of conversation afterward, when someone helps you furnish the room the medicine opened.

The Unfinished Conversation: Malika’s Story

Malika is 44, a managing director at a mid-sized investment firm, the kind of person whose calendar is color-coded by client and whose Peloton leaderboard name is a joke only three people would understand. She’d read about ketamine-assisted therapy in a newsletter a colleague forwarded her, and something about the framing, “safe,” “legal,” “clinical,” made it feel less like a risk and more like due diligence. She booked six sessions with a psychiatric provider she found through a directory. She did not, at the time, think to ask whether that provider also did integration work, because no one had told her that distinction mattered.

“I had the biggest cry of my adult life in that chair,” she told me, months later, sitting across from me with her hands wrapped around a paper cup of coffee she wasn’t drinking. “I saw my mother so clearly. I felt things about my childhood I don’t think I’d let myself feel since I was nine. And then the session ended, and the provider said ‘great work today,’ and I drove myself home, and I made dinner, and I put my kids to bed, and I just. Kept going. Like nothing had happened. Except everything had happened.”

Sitting with Malika that day, I felt the particular ache I’ve come to associate with this exact story, told by different women in different rooms with different mothers. Not surprise. Something closer to recognition, and underneath it, a kind of grief for how much genuine courage had gone into those six sessions with no one there to receive what came up.

Her body kept trying to process what her calendar had no room for. She’d wake at 3 AM with her heart pounding, the memory of her mother’s hands at the sink surfacing again with nowhere to go. She tried journaling. She tried a meditation app. The insights that had felt so vivid in session grew foggier by the week, crowded out by board decks and her son’s soccer schedule. The neuroplastic window that had felt so wide open in that chair was closing, and the old patterns that had kept her safe and functional for four decades were reasserting themselves right on schedule.

What happened to Malika wasn’t a failure of the medicine. Ketamine did precisely what it’s understood to do: it opened a door. What was missing was anyone qualified to walk through that door with her afterward. I’ve come to call this the unfinished conversation, the gap between a psychedelic session and the sustained relational work that determines whether what surfaced becomes integrated or simply forgotten. For women carrying the kind of early relational patterns described in our piece on why driven women are the hardest nervous systems to heal, that unfinished conversation isn’t a minor gap. It’s the entire difference between an experience and a transformation.

What Does Skilled Psychedelic-Assisted Therapy Actually Look Like?

Skilled psychedelic-assisted therapy is not a client taking a substance while a clinician watches the clock. The therapist’s role is active at every stage, before the session, during it, and for months after.

Before any medicine enters the picture, there’s a real preparation phase. Building rapport. Setting clear intentions. Taking a genuine trauma history, not a checklist. This groundwork is where the therapeutic alliance gets built, and the alliance determines whether the altered state that follows feels held or terrifying.

During the session itself, the therapist holds a steady, non-directive presence. Bessel van der Kolk, MD, psychiatrist and author of The Body Keeps the Score, has spent decades arguing that felt safety is the precondition for trauma healing, not a nice-to-have alongside it. His 2014 book is the one I hand to clients who want to understand why the relationship in the room matters as much as anything happening in the nervous system. In psychedelic work, that steady presence is often what allows someone to stay with difficult material instead of shutting down through it.

After the session, the real work begins. This is where a therapist’s training in relational trauma earns its keep. We help clients process what surfaced and connect it to their actual lives: their marriages, their leadership styles, their relationship to rest. This can involve somatic work, cognitive processing, or parts work, aimed at weaving the psychedelic experience into a coherent story of healing rather than a strange thing that happened once.

I read Gabor Maté’s When the Body Says No early in my training and I still think about his central argument: that chronic suffering has roots, and those roots deserve curiosity rather than a quick fix. Gabor Maté, MD, physician and trauma specialist, makes the case that symptoms are the body’s honest reporting, not its malfunction. In psychedelic integration work, we use the openness the medicine created to follow those roots down, rather than settling for the temporary relief of the session alone. This is sustained work, and it’s what keeps the gains from fading.

You can find the specific clinical detail for this work in our posts on psychedelic integration therapy and ketamine-assisted psychotherapy, both written for driven women exploring this specific territory.

Both/And: The Medicine Matters AND the Therapy Matters

It’s easy to fall into an either/or trap here. Is it the medicine that heals, or is it the therapy? In my clinical experience, it’s unequivocally both, and treating this as a competition misses the actual mechanism. Psychedelics aren’t a replacement for therapy. They’re a catalyst that can accelerate and deepen therapeutic work that’s already happening, or that begins alongside them. The future of trauma treatment isn’t medicine or therapy. It’s medicine inside therapy.

The compounds themselves, whether MDMA, psilocybin, or ketamine, have real pharmacological effects. They can lower defensiveness, widen emotional access, and create a felt sense of connection that’s genuinely difficult to reach in conventional talk therapy alone. Franz Vollenweider, a psychiatrist who has spent decades researching the neurobiological effects of psychedelics at the University of Zurich, has documented how these substances can induce altered states of consciousness with real therapeutic potential when they’re properly guided. That last clause is the whole argument. Properly guided is not optional.

That same openness is a double-edged sword. Without a therapist’s guidance and a real relational container, the material that surfaces can stay unintegrated, and unintegrated material tends to show up later as confusion, distress, or in the more serious cases, genuine harm. The therapist is the one who connects the profound and often disorienting content of a psychedelic session to a client’s actual relational patterns and beliefs about herself.

What I see consistently in my office is that the medicine can open a door, but it’s the ongoing therapeutic relationship that helps a client walk through it and build something more resilient on the other side. It’s the steady, repeated presence of another trustworthy person that teaches an overworked nervous system that safety is actually possible, that being vulnerable doesn’t end in punishment, and that change that lasts is achievable, not just a nice idea.

The medicine provides the push. The therapy provides the direction and the staying power. This isn’t a minor detail. It connects directly to the broader argument in the stress behind the stress, that the therapeutic relationship isn’t peripheral to a woman’s health. It’s upstream of nearly everything else.

The Systemic Lens: The “One and Done” Narrative and Industry Incentives

There’s a systemic force shaping this entire conversation that’s worth naming directly. As psychedelics move toward mainstream medical acceptance, venture capital has moved in with them, and venture capital tends to prefer a story that’s easy to sell. “One session, permanently changed” is a much better pitch deck than “months of relational work, most of it unglamorous.” The commercial incentive runs directly counter to the clinical reality, and that mismatch has real consequences for the women reading this.

This isn’t accidental drift. It’s structural. A single dose of medicine is a product with a clear unit economics story. Months of integration therapy is a service that requires trained clinicians, ongoing relationship, and a business model that doesn’t scale the way an app does. Which story gets funded and marketed more aggressively should not be a mystery.

In my practice, I see the fallout of that marketing regularly. Women arrive hoping for the instant transformation the marketing implied, and when the real work of integration turns out to still be ahead of them, some feel disappointed or, worse, like they personally failed at something that was supposed to be automatic. That disappointment isn’t a personal failing. It’s the predictable result of being sold a story that was never true.

Michael Pollan’s How to Change Your Mind traces the history of this field with real care, and even Pollan, who is broadly enthusiastic about psychedelics’ potential, stops well short of presenting them as a cure-all. He argues for careful stewardship as these substances re-enter mainstream use. I keep returning to that caution because it’s the piece the marketing tends to leave out. Wider access without an accompanying ethical and clinical framework doesn’t expand healing. It just expands risk.

Of course this is complicated. The current medical model often struggles with anything that resists a tidy diagnostic box, and the relational, deeply subjective nature of psychedelic-assisted work doesn’t fit neatly into existing healthcare structures built around fifteen-minute visits and standardized protocols. That mismatch is a systemic problem, not a reason to avoid the work. It’s a reason to be honest that the medicine is one key in a much larger process, not the entire lock.

What the Research Still Doesn’t Know

I want to be direct about the limits of current research, because the marketing tends to skip this part. Most published trials, including the MDMA-assisted therapy research reviewed below, involve carefully screened participants and controlled clinical settings that look nothing like a weekend retreat or an unsupervised session at home.

Long-term outcome data is still limited. We have strong early signals for conditions like treatment-resistant PTSD, and we don’t yet have decades of follow-up data the way we do for more established treatments. Ketamine is the only one of these substances currently approved for clinical use outside a research trial. Psilocybin and MDMA remain investigational.

None of this means the research isn’t promising. It is. It means anyone considering this path deserves the full picture. This article is educational, and it isn’t a substitute for a conversation with a licensed provider who knows your specific history.

What Does Meaningful Access and Healing Actually Look Like?

Meaningful access to psychedelic healing isn’t about quick fixes or isolated peak experiences. It’s about building systems that actually honor how complex trauma is, and that means prioritizing preparation and integration at least as much as the session itself, not treating them as optional add-ons.

It also means training more clinicians who are genuinely skilled in both psychedelic facilitation and relational trauma work, because those are two different skill sets and having only one of them is a real gap. A facilitator without deep trauma training may not recognize what’s surfacing in the room. A trauma therapist without psychedelic-specific training may not know how to work with the particular texture of a post-session integration conversation.

Rashida found this out the hard way before she found her way to a therapist who did both. She’s a partner at a law firm, the kind of woman who reads case law for fun and has never once missed a filing deadline in eighteen years of practice, and she’d tried two different psilocybin facilitators, both well-meaning, neither trained in trauma-informed integration, before she found someone who understood what her nervous system was actually doing.

“The first two just kept asking me what I ‘learned,'” she said, sitting in my office in the gray blazer she wears like armor, “like there was supposed to be a takeaway I could write on a sticky note. What actually happened was I relived my dad leaving, in full body detail, and nobody knew what to do with that except tell me it was ‘part of the process.’ I didn’t need a vague metaphor. I needed someone who knew what to do with a forty-three-year-old woman shaking on their couch.”

Of course she was angry. Of course two rounds of facilitation without adequate trauma training left her feeling more raw than resolved. Her anger wasn’t a character flaw or a sign she wasn’t “ready” for the work. It was an accurate read on a real gap in her care. Once Rashida found a therapist trained in both modalities, the integration work took months, not one epiphany, and by her account it was the months that actually changed how she moved through her life, not the sessions themselves.

Imagine a future where a driven woman carrying real trauma can access this kind of care not as a last resort, but as a genuinely supported path, one where she isn’t left alone with whatever surfaces. She’s guided by someone who helps her weave new material into a coherent sense of self and build trustworthy relationships, not only with her therapist, but everywhere else in her life too.

This vision of healing is communal, not solitary. We heal in relationship, and a future worth wanting is one where the conversation about trauma doesn’t just get started by a powerful molecule. It gets finished inside an actual therapeutic relationship, a space where whatever surfaced can be understood rather than felt once and filed away.

I still think about Malika’s kitchen at 6 AM, and about how different that morning might have looked if someone had told her, before her first session, that the six sessions were the beginning of the work rather than the work itself. The women I see thrive after psychedelic experiences are the ones who commit to what comes after: the ongoing, unglamorous, deeply worthwhile relational work of therapy. That commitment is what turns a powerful experience into something that actually holds.

If you’re exploring psychedelic-assisted therapy or ketamine-assisted psychotherapy, the posts on psychedelic integration therapy and KAP for driven women go deeper into the clinical detail. Individual therapy and a complimentary consultation are both available if you’re building the container for this work. The post on complex PTSD provides useful context for the kind of trauma complexity that psychedelic therapy is often asked to address, and the Strong & Stable newsletter is where I keep having this conversation, every Sunday, with the nuance this topic actually deserves.

Warmly, Annie.

Related Reading

Carhart-Harris, Robin L., and Karl J. Friston. “REBUS and the Anarchic Brain: Toward a Unified Framework for the Action of Psychedelics.” Pharmacological Reviews 71, no. 3 (2019): 316-344.

Pollan, Michael. How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. New York: Penguin Press, 2018.

van der Kolk, Bessel A. The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma. New York: Viking, 2014.

Vollenweider, Franz X., and Michael Kometer. “The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Psychiatric Disorders.” Nature Reviews Neuroscience 11, no. 9 (2010): 642-651.

Maté, Gabor. When the Body Says No: Understanding the Stress-Disease Connection. Hoboken, NJ: John Wiley & Sons, 2011.

Kryskow, Pamela, et al. “Psychedelic-Assisted Psychotherapy: A New Paradigm for Mental Health Care.” Canadian Medical Association Journal 194, no. 1 (2022): E1-E2.

References

Peer-Reviewed Research (Vancouver)

1. van der Kolk BA, Wang JB, Yehuda R, Bedrosian L, Coker AR, Harrison C, et al. Effects of MDMA-assisted therapy for PTSD on self-experience. PLoS One. 2024;19(1):e0295926. doi:10.1371/journal.pone.0295926. PMID: 38198456.

Books & Cultural Sources (Chicago Author-Date)

• Maté, Gabor. When the Body Says No. A.A. Knopf Canada, 2003.

Medical Disclaimer